Ionis earns $30 million upfront, with $300 million more possible, in massive deal with AstraZeneca
In the latest of its growing list of biomedical partnerships, Ionis Pharmaceuticals will get $30 million upfront from drug giant AstraZeneca to commercialize a drug for a genetic form of kidney disease.
Up to an additional $300 million may be available to Ionis in milestone payments as the drug progresses through clinical testing, Carlsbad-based Ionis said Monday. And if the drug reaches the market, Ionis will get “low double-digit royalties.”
The drug, called Ionis-AZ5-2.5Rx, uses an improved version of the company’s antisense technology, which treats diseases by modifying or blocking production of the disease-related proteins. This “generation 2.5” technology makes more potent drugs, and enables them to reach more regions of the body, Ionis says.
Antisense can reach disease targets other drug technologies can’t and also reduces drug side effects.
Read more: http://www.sandiegouniontribune.com/business/biotech/sd-me-ionis-deal-20180220-story.html
Up to an additional $300 million may be available to Ionis in milestone payments as the drug progresses through clinical testing, Carlsbad-based Ionis said Monday. And if the drug reaches the market, Ionis will get “low double-digit royalties.”
The drug, called Ionis-AZ5-2.5Rx, uses an improved version of the company’s antisense technology, which treats diseases by modifying or blocking production of the disease-related proteins. This “generation 2.5” technology makes more potent drugs, and enables them to reach more regions of the body, Ionis says.
Antisense can reach disease targets other drug technologies can’t and also reduces drug side effects.
Read more: http://www.sandiegouniontribune.com/business/biotech/sd-me-ionis-deal-20180220-story.html
